Drugs (selected) in clinical development designed to produce acute and/or enduring therapeutic effects in anxiety disorders. Depicted are also novel drug-assisted psychotherapeutic approaches utilizing neuroplasticity/cognition enhancing effects of drugs.
AVN-101: (CD-008-0045 licenced as AVIANDR in Russia) antagonist at 5-HT2A, 2C, 6 and 7 receptors, adrenergic 2A, 2B and 2C receptors and histamine H1 receptors; BNC210: α7-nAChR negative allosteric modulator (NAM); CBD: cannabidiol; ITI-1284: deuterated form of lumateperone, targets 5-HT2A, D2 receptors and SERT (serotonin transporter); LSD: lysergic acid diethylamide; MDMA: 3,4-Methylendioxy-N-methylamphetamin; PAMs: positive allosteric modulators (PAM) of the GABA-A receptor; SEP-363856: 5-HT1A receptor and TAAR1 (trace amine-associated receptor 1) agonist.
Related content
Suicidal ideation is far more common than attempts in people with anxiety or depression, especially with comorbid disorders and severe depression.